Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies ...

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of ...

For the full year 2025, delivered revenue of $1,305M an increase of 30% Y/Y. For 2025, generated net cash provided by operating activities of $199M, an increase of 49% Y/Y, and margin of 15%, and free ...

Highlights for the three months and year ended December 31, 2025 include (dollars in thousands, except for average PMPM fees and revenue per case): ...

Sales for the fourth quarter of fiscal 2025 were $38.2 billion, a decrease of $1.5 billion, or 3.8% from the fourth quarter of fiscal 2024. The fourth quarter of fiscal 2025 consisted of 13 weeks ...

Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted ...

Preferreds bridge bonds and equities, historically offering higher income than bonds with typically lower volatility than stocks. Read more here.

Achieved record revenue, operating income and adjusted EBITDA in the fourth quarter Signed long-term license agreement with Disney; two of the largest OTT providers now under licenseReduced debt by $6 ...

IFRS 18 does not change the accounting rules for recognising revenue, valuing assets or measuring expenses. Instead, it changes the layout and discipline of financial reporting.

On February 11, 2026, Great Lakes announced that it had entered into a definitive agreement for Saltchuk Resources, Inc.

The 2026 tax season, marked by new regulations and IRS staffing challenges, significantly increases error risks, making early preparation essential. Here 10 moves.

Discover the synergy between income statements, balance sheets, and cash flow statements for a full analysis of a company's financial health and performance.